Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: INSM

Insmed Incorporated

Healthcare | Biotechnology

No licensed closing price on file for INSM. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-4.12

Insmed Incorporated (NASDAQ: INSM) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:51 UTC.

What Insmed Incorporated does

Insmed is a biopharmaceutical company that develops and commercializes therapies organized around three therapeutic areas: Respiratory, Immunology Inflammation, and Neuro Other Rare. The company has two approved commercial products, ARIKAYCE for MAC lung disease and BRINSUPRI for non-cystic fibrosis bronchiectasis, both in the Respiratory area. Beyond its marketed products, Insmed maintains a clinical pipeline that includes programs in development for various serious lung conditions, inflammatory diseases, and rare neurological disorders.

Summarized from Insmed Incorporated’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-4.12
Debt/equity0.72

Revenue, margins & earnings

FY2021: net loss $435M on revenue $188M$188MFY2021FY2022: net loss $482M on revenue $245M$245MFY2022FY2023: net loss $750M on revenue $305M$305MFY2023FY2024: net loss $914M on revenue $364M$364MFY2024FY2025: net loss $1.28B on revenue $606M$606MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-11
  • 2026-09-11DirectorSale-25,000$3.10M
  • 2026-08-19DirectorSale-5,000$637.6K
  • 2026-08-12Chief Operating OfficerSale-239,850$31.96M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Insmed Incorporated do?

Insmed is a biopharmaceutical company that develops and commercializes therapies organized around three therapeutic areas: Respiratory, Immunology Inflammation, and Neuro Other Rare.

When did INSM last file with the SEC?

Insmed Incorporated's most recent SEC filing on record is a 8-K filed 2026-05-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:51 UTC. This page is also available as JSON at /api/data?ticker=INSM and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for INSM and 5,000+ tickers.

Create a free account — keep INSM
For your agent
GET /api/data?ticker=INSM

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt